Key Highlights

  • Tiziana Life Sciences entered into a Memorandum of Understanding with King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases.
  • The collaboration will evaluate intranasal foralumab in combination with anti-CD20 therapy.
  • The trial targets non-responding RRMS patients.
  • The collaboration broadens Tiziana's MS pipeline beyond its active, blinded Phase 2 na-SPMS study slated for an October readout.

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) entered into a Memorandum of Understanding alongside King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases to evaluate intranasal foralumab in combination with anti-CD20 therapy within a clinical trial targeting non-responding relapsing-remitting multiple sclerosis patients.

Company Overview

Tiziana Life Sciences is a clinical-stage biotechnology company focused on developing novel immunomodulatory therapies for a range of inflammatory and neurodegenerative conditions. Its lead asset, foralumab, is a fully human anti-CD3 monoclonal antibody administered intranasally, designed to modulate immune activity in the central nervous system while minimizing systemic immune suppression.

The company has pursued multiple sclerosis as a core focus area for foralumab, running trials across different MS subtypes, including its ongoing Phase 2 study in non-active secondary progressive MS, while this new collaboration with KAIMRC extends the foralumab development program into relapsing-remitting patients who have not responded adequately to existing anti-CD20 therapies.

What Happened

This collaboration broadens Tiziana's MS pipeline past the active, blinded Phase 2 na-SPMS study slated for readout in October, adding a distinct patient population and combination-therapy approach to the company's overall foralumab development strategy.

Market Reaction

The disclosed information does not include stock price or trading data for Tiziana Life Sciences following the MOU announcement.

Outlook

The October readout for the ongoing Phase 2 na-SPMS study represents the more immediate near-term catalyst for Tiziana, with the new KAIMRC collaboration representing a longer-term pipeline expansion opportunity for foralumab in relapsing-remitting MS.